|
HS Code |
918640 |
As an accredited 3-Bromopyrazole[1,5-A]Pyrimidine factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 3-Bromopyrazole[1,5-A]Pyrimidine prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Chemistry labs have come a long way from the days of struggling with sluggish reactions and unreliable intermediates. A compound like 3-Bromopyrazolo[1,5-a]pyrimidine has quietly made life easier for both academic researchers and R&D teams. For scientists working on complex organic synthesis or exploring new pharmaceutical candidates, this heterocycle offers surprising benefits. I’ve spent years in the lab evaluating building blocks and know that a single functional group’s placement can dictate a project’s entire trajectory. In the case of 3-Bromopyrazolo[1,5-a]pyrimidine, the way the bromine atom activates the pyrazolo[1,5-a]pyrimidine core opens up more than a few routes to functionalize the molecule selectively.
Projects calling for pyrimidine-based scaffolds often meet a bottleneck at the modification step. Traditional derivatives, especially unsubstituted or non-halogenated pyrazolopyrimidines, typically resist transformation under mild conditions. Chemists working with these compounds face poor yields or unwanted byproducts. Introducing a bromine at the 3-position changes that story, providing a reactive handle primed for Suzuki or Buchwald coupling reactions. This means diversification happens faster and more cleanly. I’ve seen teams cut reaction times—sometimes by half—simply by switching out a less reactive core with this bromo-substituted version.
Specification Insight and Lab Experience
3-Bromopyrazolo[1,5-a]pyrimidine carries a molecular structure that invites creativity. Its molecular formula, C6H4BrN3, clocks in with a molecular weight just shy of 200 g/mol. That’s a sweet spot for library design—large enough to serve as a recognizable fragment, yet light enough to leave room for further elaboration. In the solid state, it presents as a pale solid, approachable for standard handling in the benchtop setting. I’ve observed that even under ambient conditions, this compound remains stable for months in its original packaging—no need to scramble for extra refrigeration or special desiccants, a relief in crowded research spaces.
Solubility has tripped up many an ambitious synthesis, yet this bromo-heterocycle dissolves well in common solvents like DMSO, DMF, or even ethanol. Students new to fragment expansion or skilled process chemists pushing for scale-up will appreciate its predictability. The melting point generally falls in a modest range, sidestepping the headaches of compounds that decompose too fast or arrive as sticky oils. Small victories at the bench add up over the long haul of research cycles, and the reliability of this compound frees up time for real scientific rigor rather than troubleshooting.
Practical Usage in Modern Synthesis
Talking with colleagues over coffee, I often hear tales of synthesis campaigns stalled by reluctance to adopt new intermediates. Yet the tide is unmistakably shifting. One primary reason: 3-Bromopyrazolo[1,5-a]pyrimidine acts as a flexible intermediate for building target molecules—particularly those targeting kinase inhibition, inflammation, or CNS pathways. The pyrazolopyrimidine ring draws interest from medicinal chemists searching for privileged scaffolds that hit tough targets.
Having run more attempts at coupling reactions than I can count, I can say with confidence that the bromine atom’s placement in this structure is a game changer. It’s more than just a point for traditional cross-coupling. The electron distribution in the ring system also influences regioselectivity in subsequent transformations. For instance, borylation or amination reactions run cleaner when starting from this intermediate, sidestepping the tedium of purifying messy reaction mixtures. In medicinal chemistry programs, teams regularly use this compound as a launching point for SAR (structure-activity relationship) exploration, quickly generating analog libraries without complex protecting group strategies.
Comparisons with Similar Compounds
It’s easy to see why the 3-bromo derivative pulls ahead of its siblings. Compare it to the unsubstituted pyrazolopyrimidine core: those often lack the reactivity for direct functionalization and act as bottlenecks in the synthetic route. The 3-chloro and 3-iodo versions also exist, yet the bromine variant strikes a better balance between reactivity and stability. The iodo version, while more reactive, tends toward decomposition and sometimes proves hard to handle. The chloro compound, less reactive, often requires harsher conditions, putting delicate motifs at risk. In my experience, the 3-bromo bridge provides the “just right” Goldilocks scenario; most coupling chemistries developed for modern libraries match well with this intermediate.
Unlike isomeric variants or similar halogenated compounds, 3-Bromopyrazolo[1,5-a]pyrimidine responds consistently to a wide array of established protocols. Labs moving from small-scale discovery to pilot plant operations report that purity remains high across multiple batches, and crystalline forms ease both isolation and handling. The absence of difficult side-products means waste disposal—often a thorny subject in scale-ups—remains straightforward.
Applications Across Discovery and Scale-Up
The push for new anticancer, antiviral, and neuroprotective drugs has created fierce demand for heterocyclic intermediates that don’t slow project timelines. In this race, 3-Bromopyrazolo[1,5-a]pyrimidine stands out as a workhorse for lead optimization. I’ve seen it incorporated in both fragment-based drug design and more traditional hit-to-lead pathways. Researchers appreciate how quickly analog libraries can be expanded without sacrificing purity or yield. Less time wasted repeating failed couplings means more energy focused on meaningful biology.
Beyond drug discovery, synthetic organic chemists draw on this compound when designing molecular probes or chemical biology tools. Its core structure provides a skeleton that tolerates diverse substitutions, offering access to unique analogs for screening studies. I recall one collaboration where our team needed a probe to map a new signal transduction pathway; using the bromo derivative, we attached fluorophores and affinity tags in a couple of straightforward steps. This efficiency prompted the team to commit further resources, knowing that future modifications would be equally manageable.
Industrial chemists, too, report smoother development cycles using this intermediate. The reliability seen at the gram scale translates up to kilogram batches, with minimal process optimization required. In pharmaceutical process groups, attention often centers on whether a key intermediate will “play nice” with other ingredients. Here, the bromo-pyrazolopyrimidine holds its own. Long-term storage stability means fewer worries about batch-to-batch inconsistency, while resistance to hydration or oxidation relieves a common logistical headache.
The Value Proposition: Efficiency, Reliability, and Safety
Cutting corners rarely pays off in synthetic chemistry. Over the years, plenty of synthesizers have chased lower-cost or more “exotic” building blocks, only to circle back to proven performers that reliably deliver. 3-Bromopyrazolo[1,5-a]pyrimidine falls in this category. By providing solid reliability without dangerous reactivity, it strikes a comfortable balance for both bench chemists and safety officers. Unlike some functionalized heterocycles prone to decomposition under moderate heat, this compound rarely gives off problematic fumes or hazardous breakdown products under routine lab use. Such characteristics matter a lot, especially for educational labs or early-stage startups managing limited resources and inexperienced hands.
The safety profile is worth further mention. Pyrazolopyrimidines as a class generally register low acute toxicity and low volatility. Handling this bromo variant mirrors routine aromatic bromides. No need for exotic ventilation setups beyond the standard fume hood precautions. Having personally managed research involving both seasoned professionals and undergraduates, I see firsthand how lowering the risk factor means fewer accidents and less time spent on safety briefings at the expense of real laboratory work.
Environmental and Regulatory Aspects
Any compound making its way into modern research pipelines faces scrutiny from a regulatory and sustainability lens. 3-Bromopyrazolo[1,5-a]pyrimidine scores well here. Its manageable hazard rating means that the elaborate controls demanded for more problematic intermediates aren’t required. In practice, I’ve seen both academic and industrial labs pass environmental health and safety audits with minimal changes to their standard operating procedures.
Waste management remains an eternal concern for scale-up settings, but this intermediate generally avoids generating difficult or persistent waste. Existing guidelines for aryl bromides cover its disposal and recovery, sparing research teams the burden of hunting down compound-specific incineration or treatment procedures. Sustainable practices call for intermediates that don’t sabotage green chemistry initiatives, and this molecule works well within those parameters.
Challenges and Solutions in Sourcing and Use
No compound, no matter how versatile, solves all synthetic chemistry challenges. The growing popularity of 3-Bromopyrazolo[1,5-a]pyrimidine has sometimes caused short-term sourcing hiccups. Many labs struggle with supplier bottlenecks or inconsistent documentation, occasionally finding small differences in impurity profiles between vendors. I’ve experienced this myself, tracking melting point variations and subtle changes in NMR purity when switching suppliers. The answer isn’t to skip this valuable intermediate but to engage with reputable sources that provide certificates of analysis and batch records. Whenever quality variation creeps in, labs can institute routine incoming QC checks—simple strategies like running a reference NMR or validating melting points before green-lighting a new lot.
International shipping and customs controls present another real-world obstacle. Because this compound fits into the broader category of controlled heterocycles in some regions, paperwork delays can impede project timelines. Through direct experience, I’ve found preemptively communicating regulatory status to customs brokers and maintaining a buffer stock can smooth out these bumps. While not unique to this compound, any intermediate straddling multiple regulatory environments benefits from a documented chain of custody and clear end-use declarations. In the long run, these practices ensure research doesn’t end up derailed by bureaucratic complications.
Responding to the Needs of Modern Chemistry
Innovation in synthetic chemistry rarely happens in isolation. Labs across the globe share a collective demand for reliable, versatile intermediates, especially for drug discovery and diversified molecular design. 3-Bromopyrazolo[1,5-a]pyrimidine stands out by supporting both exploratory research and process development. As scientists push into new therapeutic spaces, this compound remains relevant. It adapts well to traditional synthetic transformations as well as the newest protocols in cross-coupling and functional group exchange.
Working alongside colleagues tackling evolving medicinal challenges, I recognize how the modularity of this intermediate helps cut through barriers. Lead optimization often needs hundreds of analogs within months—a task that breaks down slower intermediates and convoluted synthetic steps. The bromo group’s reactivity means one can pivot quickly to introduce bulkier or more polar substituents, feeding into the fast-paced cycles demanded by stakeholders. Having seen my own teams meet frantic deadlines, I credit user-friendly building blocks like this for allowing the flexibility to adapt strategies on the fly.
For startup biotech firms and academic innovators working on limited budgets, the ability to stretch small quantities across dozens of experiments is invaluable. I’ve known junior researchers to push a single gram through more than a dozen reaction schemes, exploring everything from simple Suzuki couplings to sophisticated tandem cascades. This capacity to enable wide-ranging experiments without repeated procurement appeals to both cost-conscious management and ambitious young chemists charting new territory.
Solutions for Common Pitfalls
Even established intermediates bring unique learning curves. Stubborn purification steps or batch-to-batch impurity drift occasionally pop up in practice. From hands-on stints in the lab, I recommend optimizing crystallization protocols first—adjusting solvent systems or adding seeding steps can improve both yield and purity. For reactions at ultra-low scale, using prepacked silica columns or switching to reverse-phase chromatography helps handle trickier separations.
Another solution comes from documentation. Keeping detailed notes on batch sources, solvent quality, and storage conditions helps uncover patterns that might escape notice at first glance. Not every impurity or reaction failure results from the intermediate itself; frequently, inconsistent solvents or overheated glassware introduce noise. Instituting routine process checks keeps teams moving forward, letting the chemistry rather than avoidable error dictate project success.
As for broader project timelines, open sharing of synthetic methods and pitfalls among teams saves time and resources. I’ve seen consortia of research groups pool data about best coupling catalysts, purification tricks, and reaction conditions unique to this intermediate. This culture of transparency means new researchers avoid the “reinventing the wheel” trap that commonly derails early-stage chemistry campaigns.
Looking Forward: Expanding Access and Applications
With the world’s focus on rapid biomedical innovation, intermediates like 3-Bromopyrazolo[1,5-a]pyrimidine will only grow more crucial. Advances in high-throughput experimentation, AI-aided molecular optimization, and automated synthesis platforms point to a future where such versatile building blocks streamline both screening and scale-up. I’ve already seen cheminformatics teams prioritize scaffolds proven to handle diverse further modification, and this bromo-heterocycle ranks high on those lists.
One area ripe for development revolves around improving sustainable sourcing. While aryl bromides are relatively common, greener manufacturing routes—low-waste and minimal residual metal contaminants—promise further benefits for users and the environment. Labs that invest in reliable purification steps or contract with suppliers offering green chemistry credentials will set a new standard for responsible science.
Mentoring upcoming scientists, I urge them to stick with the intermediates that deliver results across multiple projects. 3-Bromopyrazolo[1,5-a]pyrimidine, with its blend of accessibility, reactivity, and reliability, remains a favorite in my experience. From bench-scale proof-of-concept to preclinical process development, it paves the way for safer, more flexible, and more innovative chemistry. For every lab wrestling with time and resource constraints, a trustworthy intermediate provides not just a chemical advantage but peace of mind—a foundation upon which the next big breakthrough rests.